Jessica Devin is an Endocrinology/Metabolic physician affiliated with UCHealth Yampa Valley Medical Center. OpenAlex indexes 45 publications with 828 citations (h-index 18); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1100 Central Park Dr Ste 200
Steamboat Springs, CO 80487
Telephone
000-000-0000Registry record last updated 19 Sept 2018.
Clinical trials
- The Effect of Dipeptidyl Peptidase 4 Inhibition on Growth Hormone Secretion in Women With Polycystic Ovarian Syndrome
Sponsor: Vanderbilt University
- Effect of DPP4 Inhibition on Growth Hormone Secretion
Sponsor: Vanderbilt University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Dexcom, Inc.Program year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
54.8%Insulin Analog19.5%Tresiba Flextouch U-10028%Tresiba Flextouch U-20021%Lantus Solostar17%Novolog Flexpen11%Humalog Kwikpen U-10010%Basaglar Kwikpen U-1007%Insulin Lispro7%Part D<11 patientsGLP-1 receptor agonist16.4%Ozempic38%Trulicity34%Mounjaro28%Part D<11 patients+ 5 more classes in this area
Hormonal (systemic)
32.4%l-Thyroxine24.6%Levothyroxine Sodium56%Synthroid44%Part D≥31 patientsParathyroid Hormone-Related Peptide Analog2.7%Tymlos100%Part D<11 patients+ 3 more classes in this area
Cardiovascular
6.6%Statin3.9%Atorvastatin Calcium100%Part D≥12 patientsACE inhibitor1.5%Lisinopril100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- RISING STARS: Effects of a GLP-1 receptor polymorphism on responses to liraglutide
Journal of Endocrinology
2025 - 7742 Clinical Outcomes of Thyroid Cancer Patients Enrolled in a Comprehensive Thyroid Cancer Survivorship Program
Journal of the Endocrine Society
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Bruce Bartholow Duncan
Universidade Federal do Rio Grande do Sul
Alireza Esteghamati
Tehran University of Medical Sciences
Paul Zimmet
Monash University
André Pascal Kengne
South African Medical Research Council
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”